29 August, 2015 LONDON, UK – The ESC today announced the launch of its new ESC Grants for Medical Research Innovation, an ambitious programme sponsored exclusively by Boehringer Ingelheim, aimed at stimulating worldwide research in cardiovascular medicine.
“This grant project is a reflection of the ESC’s commitment to encouraging new and innovative research aimed at improving patient outcomes in thromboembolic disease – a leading cause of mortality worldwide,” said Professor Francesco Cosentino, the chair of the programme’s scientific committee.
“It is estimated that one in four people die as a result of thromboembolic disease, which causes abnormal blood clotting, and more research into this disorder is urgently needed,” he said.
The programme, offers four grants, to a maximum of €400,000 each, which will be awarded to independent interventional and observational research projects in the areas of atrial fibrillation, stroke, deep vein thrombosis/pulmonary embolism, percutaneous coronary intervention, coronary artery disease and/or peripheral artery disease.
“We are excited about this initiative because it is a great opportunity to perform important studies aiming to a better understanding of novel therapeutic strategies in this setting,” said Prof. Cosentino.
“We are now ready to receive applications from around the world for these prestigious grants - until the November 1st deadline - and look forward to announcing the four winners at European Heart House on December 1st following live presentations by all finalists.”
Eligible research should run no longer than 18 months and have publishable outcomes to be presented at ESC Congress 2017.
Applications may be made via this dedicated webpage: www.escardio.org/innovationgrants.
-- END --
Our mission: To reduce the burden of cardiovascular disease.